Back to today’s briefing

Story perspectives

Aclaris Therapeutics Sees 12.7% Short Interest Spike, Director Buys 666,666 Shares

1/19/2025

32 5

Summary

Story summary

Aclaris Therapeutics (NASDAQ: ACRS) saw a significant 12.7% increase in short interest, reaching 3,560,000 shares by year-end. In a bold move, Director Anand Mehra acquired 666,666 shares at $2.25 each. With analysts now favoring the stock with a "Buy" rating and a target price of $11.00, Aclaris is poised for growth in immune-inflammatory disease therapies.

1 of 1

Story summary

Aclaris Therapeutics (NASDAQ: ACRS) saw a significant 12.7% increase in short interest, reaching 3,560,000 shares by year-end. In a bold move, Director Anand Mehra acquired 666,666 shares at $2.25 each. With analysts now favoring the stock with a "Buy" rating and a target price of $11.00, Aclaris is poised for growth in immune-inflammatory disease therapies.